VA/DoD guideline discourages stopping an effective obesity medication

The U.S. Department of Veterans Affairs and Department of Defense released an updated clinical practice guideline for managing overweight and obesity in adults, and a synopsis for primary care clinicians was published in Annals of Internal Medicine ^[1][2]. Two points stand out for people taking GLP-1 medications: the guideline "discourages discontinuation of effective medications to prevent weight regain," and it found insufficient evidence to recommend for or against delaying drug treatment relative to lifestyle programs, with "no requirement to complete CLI before initiating additional treatments" ^[1][2].

CLI stands for comprehensive lifestyle intervention — a program that always includes behavioral, dietary, and physical activity components. The work group still gives that a "strong for" recommendation as the foundation of care, delivered in person as a group or individual program ^[2]. But the 2025 update explicitly supports "flexible, individualized integration of pharmacotherapy and CLI" rather than a strict step-by-step order ^[1][2].

How the guideline was built

The VA/DoD Evidence-Based Practice Work Group convened a multidisciplinary panel of VA and DoD clinicians, and an independent third party, Sigma Health Consulting, ran the evidence review ^[2]. The team wrote 12 key questions and searched peer-reviewed literature published from 1 April 2019 through 6 January 2025, prioritizing systematic reviews and meta-analyses along with individual randomized controlled trials ^[1][2]. Recommendations were graded using the GRADE system, which weighs evidence quality, the balance of benefits and harms, patient values informed by focus groups, and factors like cost, equity, and feasibility ^[1][2].

The result was 23 clinical recommendations: 8 new, 4 reviewed and replaced, 7 reviewed and amended, and 4 carried forward unchanged ^[2]. All work group members completed conflict-of-interest disclosure forms, and no financial conflicts were identified ^[2].

On screening, the work group suggests checking all adults using a body mass index of 25 kg/m² or higher — 23 kg/m² or higher for Asian adults — combined with waist circumference and clinical context to refine risk ^[1][2]. It also found insufficient evidence to favor any one measure of body fat over another, or any one diet over another for weight loss and maintenance ^[2]. For procedures, it suggests intragastric balloons for temporary weight loss at a BMI of 30 kg/m² or higher, endoscopic sleeve gastroplasty at a BMI of 30 kg/m² or higher, and metabolic and bariatric surgery at a BMI of 30 kg/m² or higher with type 2 diabetes or a BMI of 35 kg/m² or higher — each alongside a lifestyle program ^[2].

The guideline says new and updated recommendations address medications containing glucagon-like peptide-1 receptor agonists, but the specific drug-by-drug recommendations and their GRADE strengths are not included in the source text available here ^[1][2].

Why the setting matters

The guideline frames obesity as "a chronic, relapsing neurohormonal disease" and notes it affects 40% of U.S. adults, with projections that 1 in 2 adults will be affected by 2030 ^[1][2]. In the military, obesity prevalence among active-duty service members rose from 10.4% in 2012 to 21.6% in 2022, with 68% having a BMI in the overweight or obesity category ^[2]. Most veterans enrolled in VA care gain significant weight within 10 years of leaving service, raising risk for high blood pressure, type 2 diabetes, cardiovascular disease, chronic pain, and metabolic dysfunction–associated steatotic liver disease ^[2].

Why it matters for patients

Many people on semaglutide or tirzepatide have run into insurance rules or clinic policies that require finishing a structured lifestyle program before a prescription is approved, or that treat the medication as a short course. This guideline, which governs care for millions of veterans and service members, does not support either framing: it found no evidence basis for requiring a lifestyle program first, and it discourages stopping a medication that is working simply to see whether weight stays off ^[1][2].

That places a large federal health system in the same position as obesity specialty groups on the continue-versus-stop question. Guidelines are not coverage rules, though, and how the VA and DoD translate these recommendations into formulary and prescribing decisions is not described in the synopsis.

What happens next

The full guideline, including the methods appendixes and details on which questions were carried forward from the 2020 version, is posted by VA Health Quality ^[2]. Whether private insurers or other health systems adopt similar language on continuing effective medication is not yet known.